Chance Pharma Completes $30 Million Round for Inhalation Therapies
October 11, 2021 at 05:52 AM EDT
Chance Pharma of Hangzhou, an inhalation therapy company, completed a $30 million Series C financing led by new investor Lapam Capital. Chance intends to use the capital to advance its R&D, start new business collaborations and accelerate the construction of a manufacturing facility. Also participating in the C round were new investors CMS Capital and HEDA BioVenture and existing investor Guozhong Capital. Earlier this year, Chance signed a deal with Aerami Therapeutics to acquire greater China rights for a drug device combination product aimed at Pulmonary Arterial Hypertension. More details.... Share this with colleagues: // //
